Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients
Author
Source
Issue
Vol. 2016, Issue 2016 (31 Dec. 2016), pp.1-10, 10 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2016-08-24
Country of Publication
Egypt
No. of Pages
10
Main Subjects
Abstract EN
Hypoglycemia is the most common side effects for most glucose-lowering therapies.
It constitutes a serious risk that faces diabetic patients who fast during Ramadan (the 9th month in the Islamic calendar).
New glucose-lowering classes like dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide 1 receptor agonist (GLP-1 RA), and sodium-glucose cotransporter-2 (SGLT-2) inhibitors are efficacious in controlling blood glucose level with less tendency to induce hypoglycemia and thus may constitute a good choice for diabetic patients during Ramadan.
This study reviews the safety and efficacy of newer glucose-lowering therapies during Ramadan.
This study was accomplished through a careful literature search about studies that assess the benefit and side effects of these new glucose-lowering therapies during Ramadan during September 2015.
Vildagliptin, sitagliptin, liraglutide, exenatide, and dapagliflozin were the only studied glucose-lowering therapies.
All of the studied newer glucose-lowering therapies except dapagliflozin were associated with reduced risk to induce hypoglycemia.
Gastrointestinal upset was common with the usage of liraglutide while increased thirst sensation was common with dapagliflozin.
In conclusion DPP-4 inhibitors such as vildagliptin and sitagliptin may form a suitable glucose-lowering therapy option for Ramadan fasting patients.
American Psychological Association (APA)
Mudher Mikhael, Ehab. 2016. Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients. Journal of Diabetes Research،Vol. 2016, no. 2016, pp.1-10.
https://search.emarefa.net/detail/BIM-1108221
Modern Language Association (MLA)
Mudher Mikhael, Ehab. Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients. Journal of Diabetes Research No. 2016 (2016), pp.1-10.
https://search.emarefa.net/detail/BIM-1108221
American Medical Association (AMA)
Mudher Mikhael, Ehab. Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients. Journal of Diabetes Research. 2016. Vol. 2016, no. 2016, pp.1-10.
https://search.emarefa.net/detail/BIM-1108221
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1108221